Tirzepatide in Canada: A Researcher’s Buying Guide
Tirzepatide is one of the most searched research peptides on the internet, and one of the most loosely described. It is a dual GIP and GLP-1 receptor agonist, studied in laboratory settings for its action on two incretin pathways rather than one. For Canadian researchers the practical questions are the familiar ones: where to source it domestically, how it is supplied and handled, and how it actually differs from the compounds it gets grouped with.
View product →At a glance: Vistara Labs stocks tirzepatide in 10 and 20 mg vials, independently tested, with a certificate of analysis on our Lab Reports page, shipped from within Canada by Canada Post Xpresspost, with same-business-day dispatch on orders before 3 pm Pacific. We deliver to every province, including Ontario, Quebec, British Columbia and Alberta.
What dual agonism means here
The incretin system runs on two gut hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Most compounds in this class engage one of them. Tirzepatide is a single engineered peptide that binds both receptors, which is why it is described as a dual agonist rather than a combination product. That distinction matters in study design: a dual agonist is one molecule with one pharmacokinetic profile, not two compounds administered together, so the two receptor effects cannot be separated or timed independently.
Tirzepatide, semaglutide and retatrutide compared
These three are constantly confused, and the difference is simply how many receptors each one engages.
- Semaglutide targets GLP-1 alone.
- Tirzepatide targets GIP and GLP-1.
- Retatrutide targets GIP, GLP-1 and the glucagon receptor, which is why it is sometimes called a triple agonist or GLP-3.
More receptors is not automatically more of anything; it means a different pharmacological profile with different questions attached. We compare the two most often confused in retatrutide versus tirzepatide, and the whole family is written up in our GLP-1, GLP-2 and GLP-3 explainer. The published human trial literature is summarised separately in tirzepatide human trials.
Why researchers source tirzepatide domestically
Tirzepatide work tends to run as a series, which makes a steady domestic supply the practical choice, and a lyophilised peptide keeps best when it moves promptly from cold storage to the bench. Tirzepatide is held in domestic stock with free shipping on larger orders, and every order ships from within Canada, so there is no customs step (see peptides, customs and domestic shipping).
Available sizes
Tirzepatide is stocked in two vial sizes, 10 mg and 20 mg. The larger vial is the more economical per milligram, and the choice between them is usually a question of how much material a given protocol consumes before the reconstituted solution reaches the end of its useful storage window rather than a question of cost alone.
Buying tirzepatide in Canada
- Published certificates. Certificates of analysis from independent laboratories are published for each compound, and tirzepatide’s certificate reports purity above 99 percent, measured by chromatography. It sits on our lab reports page with every other compound we stock.
- The molecule. Tirzepatide is a 39 amino acid peptide built on the GIP sequence, with a C20 fatty diacid side chain that binds albumin and extends its half life to about five days in the published pharmacokinetic work, which is why it is described as a long-acting agonist.
- Format and reconstitution. Tirzepatide is supplied lyophilised in a sealed vial and reconstituted with bacteriostatic water for laboratory handling. See our bacteriostatic water explainer and the tirzepatide reconstitution guide.
- Research-use framing. In Canada these compounds are supplied strictly for laboratory research, and Vistara Labs supplies tirzepatide on that basis; see our overview of the legal landscape.
Retatrutide, the compound most often compared with tirzepatide, has its 10 mg and 20 mg certificates on the same lab reports page, alongside the other metabolic research compounds in the catalogue.
Handling and storage
The lyophilised powder is the stable form, and unopened vials are kept cold and out of the light until needed. Once reconstituted the vial is refrigerated and labelled with the date and the concentration chosen. General practice is covered in how to store research peptides. The broader compound set sits on the weight loss and metabolism research page.
Frequently asked questions
Where can I buy tirzepatide in Canada?
From domestic research suppliers. Vistara Labs stocks tirzepatide and ships from within Canada, with its certificate of analysis published on the lab reports page.
Is tirzepatide legal in Canada?
It is supplied for laboratory research use only, the same framing as other research peptides. It is not sold for human use, and nothing here is medical advice.
How is tirzepatide supplied?
As a lyophilised powder in a sealed vial, in 10 mg and 20 mg sizes, third party tested, with the purity figure published on the product page and in the lab reports table.
What is the difference between tirzepatide and retatrutide?
Tirzepatide is a dual GIP and GLP-1 agonist. Retatrutide adds glucagon receptor activity as a third pathway on top of both. The full comparison is in retatrutide versus tirzepatide.
Is tirzepatide the same as semaglutide?
No. Semaglutide engages the GLP-1 receptor only. Tirzepatide engages GIP and GLP-1, which is why it is classed as a dual agonist rather than a GLP-1 agonist.
All products discussed are for laboratory research use only and are not for human use. Nothing on this page is medical advice, and no statement about any compound is a claim of therapeutic benefit.
References
Tirzepatide has one of the largest human trial programmes of any compound in this catalogue, including multiple phase 3 trials.
- Tirzepatide Once Weekly for the Treatment of ObesityRandomised phase 3 trial; 2,539 adults with overweight or obesity without diabetes, 72 weeks.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With ObesityRandomised phase 3 withdrawal trial; 670 participants randomised after a 36-week open-label phase.
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and ObesityRandomised phase 3 trials in adults with obesity and moderate-to-severe obstructive sleep apnoea.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and ObesityRandomised phase 3 trial (SUMMIT); 731 patients with obesity-related heart failure with preserved ejection fraction.
- Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysisSystematic review and meta-analysis; 22 trials, 29,023 participants.
Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.
